Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

May 06 / 24

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 06 / 24

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 01 / 24

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 25 / 24

Belite Bio Announces $25 Million Registered Direct Offering

Apr 22 / 24

Belite Bio Initiates Stargardt Disease Clinical Trial in Japan

Apr 18 / 24

Belite Bio Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom

Mar 25 / 24

Belite Bio Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease

Mar 22 / 24

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 11 / 24

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 19 - 27 of 32

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio